473 related articles for article (PubMed ID: 32314071)
1. Peanut Oral Immunotherapy: a Current Perspective.
Patrawala M; Shih J; Lee G; Vickery B
Curr Allergy Asthma Rep; 2020 Apr; 20(5):14. PubMed ID: 32314071
[TBL] [Abstract][Full Text] [Related]
2. Current opinion and review on peanut oral immunotherapy.
Deol S; Bird JA
Hum Vaccin Immunother; 2014; 10(10):3017-21. PubMed ID: 25483680
[TBL] [Abstract][Full Text] [Related]
3. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
[TBL] [Abstract][Full Text] [Related]
4. Peanut Oral Immunotherapy: State of the Art.
Tang MLK; Lozinsky AC; Loke P
Immunol Allergy Clin North Am; 2020 Feb; 40(1):97-110. PubMed ID: 31761124
[TBL] [Abstract][Full Text] [Related]
5. Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan.
Nagakura KI; Yanagida N; Sato S; Nishino M; Asaumi T; Ogura K; Ebisawa M
Pediatr Allergy Immunol; 2018 Aug; 29(5):512-518. PubMed ID: 29603410
[TBL] [Abstract][Full Text] [Related]
6. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
[TBL] [Abstract][Full Text] [Related]
7. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
Vickery BP; Scurlock AM; Kulis M; Steele PH; Kamilaris J; Berglund JP; Burk C; Hiegel A; Carlisle S; Christie L; Perry TT; Pesek RD; Sheikh S; Virkud Y; Smith PB; Shamji MH; Durham SR; Jones SM; Burks AW
J Allergy Clin Immunol; 2014 Feb; 133(2):468-75. PubMed ID: 24361082
[TBL] [Abstract][Full Text] [Related]
8. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
[TBL] [Abstract][Full Text] [Related]
9. Allergen-specific oral immunotherapy for peanut allergy.
Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
[TBL] [Abstract][Full Text] [Related]
10. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.
Vickery BP; Berglund JP; Burk CM; Fine JP; Kim EH; Kim JI; Keet CA; Kulis M; Orgel KG; Guo R; Steele PH; Virkud YV; Ye P; Wright BL; Wood RA; Burks AW
J Allergy Clin Immunol; 2017 Jan; 139(1):173-181.e8. PubMed ID: 27522159
[TBL] [Abstract][Full Text] [Related]
11. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG
J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy approaches for peanut allergy.
Kim EH; Patel C; Burks AW
Expert Rev Clin Immunol; 2020 Feb; 16(2):167-174. PubMed ID: 31928251
[No Abstract] [Full Text] [Related]
13. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
[TBL] [Abstract][Full Text] [Related]
14. Advances in the management of peanut allergy (oral immunotherapy and epicutaneous immunotherapy).
Wang J
Allergy Asthma Proc; 2020 Jan; 41(1):5-9. PubMed ID: 31888777
[No Abstract] [Full Text] [Related]
15. Oral immunotherapy for treatment of peanut allergy.
Dunlop JH
J Investig Med; 2020 Aug; 68(6):1152-1155. PubMed ID: 32665367
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and immune regulation with peanut oral immunotherapy.
Jones SM; Pons L; Roberts JL; Scurlock AM; Perry TT; Kulis M; Shreffler WG; Steele P; Henry KA; Adair M; Francis JM; Durham S; Vickery BP; Zhong X; Burks AW
J Allergy Clin Immunol; 2009 Aug; 124(2):292-300, 300.e1-97. PubMed ID: 19577283
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for peanut allergy.
Lee TH; Chan J; Lau VW; Lee WL; Lau PC; Lo MH
Hong Kong Med J; 2014 Aug; 20(4):325-30. PubMed ID: 24948668
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
Narisety SD; Frischmeyer-Guerrerio PA; Keet CA; Gorelik M; Schroeder J; Hamilton RG; Wood RA
J Allergy Clin Immunol; 2015 May; 135(5):1275-82.e1-6. PubMed ID: 25528358
[TBL] [Abstract][Full Text] [Related]
19. Peanut oral immunotherapy in a pediatric allergy clinic: Patient factors associated with clinical outcomes.
Guarnieri KM; Slack IF; Gadoury-Lévesque V; Eapen AA; Andorf S; Lierl MB
Ann Allergy Asthma Immunol; 2021 Aug; 127(2):214-222.e4. PubMed ID: 33839246
[TBL] [Abstract][Full Text] [Related]
20. Peanut allergy and oral immunotherapy.
Lee TH; Chan JKC; Lau PC; Luk WP; Fung LH
Hong Kong Med J; 2019 Jun; 25(3):228-234. PubMed ID: 31178442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
